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Abstract:
Introduction: Daytime drooling is experienced by around 50% of 
Parkinson’s patients, who fail to swallow saliva in sufficient volume or 
regularity, despite normal production. This research explored the 
feasibility and acceptability of using a cueing device, to improve drooling. 
Methods: During a 4-week intervention, 28 participants were asked to 
use a cueing device for one hour per day. During this time, the device 
vibrated once-per-minute, reminding the participant to swallow their 
saliva. A daily diary was used to collect self-report around swallowing 
severity, frequency and duration. This was filled out by participants for 1 
week before, 4 weeks during, and for 1 week immediately after 
intervention. Diaries were also collected for 1 week during a follow up, 
carried out 4 weeks after intervention finished. 
Results: Participants self-reported benefits in drooling severity 
(p=0.031), frequency (p=<0.001), and duration (p=0.001) after using 
the device. Improvements were maintained at follow up. Twenty-two 
participants explicitly reported a positive benefit to their drooling during 
exit interview. All felt the intervention and device were acceptable and 
usable. 
Conclusions: Using a cueing device for 1 month had perceived benefit to 
drooling severity, frequency and duration in patients with Parkinson’s. 
Participants accepted the device and treatment protocol. 
 
https://mc.manuscriptcentral.com/jrate
RATE Journal
For Peer Review
Page 1 of 39
https://mc.manuscriptcentral.com/jrate
RATE Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
The Feasibility and Acceptability of using a Novel Wrist Worn 
Cueing Device to Self-Manage Drooling Problems in People 
with Parkinson’s Disease: A Pilot Study
Introduction 
Sialorrhoea, also termed termed drooling or ptyalism, is reported as a significant common 
symptom of Parkinson’s. In some studies, drooling is reported to be an issue in up to 70% of 
participants, especially if one takes into account nocturnal drooling and increasing severity 
of Parkinson’s [1-4]. Saliva is vital for good oral health. Impaired production of, or loss of 
saliva through drooling exposes individuals to a range of negative effects, from mild 
annoyance at perceived lack or excess of saliva in the mouth, to major health and psycho-
social issues. Saliva helps regulate oral pH and microbiotic homeostasis [5]. The 
antimicrobial, anti-viral and anti-fungal properties of saliva aid oral cleansing, protect 
against infection and support tissue repair. Saliva serves as a buffer against noxious 
substances. It lubricates the oral cavity, thereby supporting formation and transport of the 
food bolus to the pharynx for swallowing. It acts as a first stage in digestion and stimulates 
interaction with chemosensory receptors to aid taste and smell perception. It supports 
smooth movement of the tongue and lips for speech.  If saliva is lost through drooling the 
person with Parkinson’s (pwPD) is at risk of lowered resistance to infection, poor oral 
health, and added problems with swallowing and speech. Dry mouth – a common 
consequence of saliva loss – is associated with risks of ulceration, tooth decay, gingivitis, 
candidiasis, halitosis and perioral dermatological issues [6, 7]. In many societies the effects 
of drooling (e.g. odor, stained clothes, constant wiping) are socially frowned upon. In this 
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way drooling may influence psycho-social health for the pwPD and produce an added 
burden for the carer (e.g. washing clothes; restricted social life) [8-10]. 
In Parkinson’s , with over half of all individuals reporting diurnal (daytime) drooling 
[1]—a figure which rises even further when nocturnal drooling is taken into account [2]. 
dDrooling is associated not with excess production of saliva, but principally with muscle 
rigidity and bradykinesia of the facial, tongue and lip muscles [11-13].  PwPD who 
experience drooling fail to swallow saliva in sufficient volume or regularity, despite a normal 
amount of saliva production [11, 12]. This leads to pooling of saliva in the mouth and risk of 
anterior loss. In addition to the impaired swallow mechanism in Parkinson’s, the 
dysautonomia associated with the condition, as well as changes in sensory perception of 
food that affect salivation (smell, taste, vision) may complicate the picture [5, 7]. Cognitive 
factors may also play a role.  in the oral and pharyngeal structures [1] leading to pooling of 
saliva in the mouth. People experiencing drooling issues fail to swallow saliva in sufficient 
volume or regularity, despite a normal amount of saliva production. Nóbrega et al. [1], using 
modified barium swallow with videofluoroscopy and a drooling score, showed changes in 
the oral stage of swallowing in 100% of people experiencing drooling problems (n=16), and 
in the pharyngeal stage in 94% of patients. They also found a correlation between drooling 
severity and swallowing problems (dysphagia). People with the worst dysphagia had the 
worst drooling. In Edwards et al [3], self-reported drooling was a problem in 70% of people 
with Parkinson’s, in both the later stages and early stages of the disease. In addition, a 2017 
study by Reynolds, Miller and Walker [14], found an association between swallowing 
frequency and drooling severity, in particular during states of distraction.
Most current pharmaceutical treatments for drooling in Parkinson’s aim to decrease 
saliva production. However, there are potential complications associated with their use. 
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Firstly, as mentioned previously, lack of saliva can cause oral health problems (e.g. gingivitis, 
tooth destruction, tongue crusting) [155]. Secondly, the use of drug treatments such as 
sSublingual aAtropine can lead to serious cognitive side effects, such as memory impairment 
and/or hallucinations [166]. Botulinum toxin injection into the salivary glands can be painful 
and must be repeated every three to six months. In addition, ithis carries some risk of 
masseter and pharyngeal muscle weakness that can both impact on chewing and 
swallowing. Meningaud et al. [155] extensively reviewed the modalities of treatment for 
drooling problems and maintained that it is important to propose, where feasible, non-
invasive treatment options, such as behavioral cueing methods, before drug or surgical 
therapy is considered. Recent major guidelines underline the importance of this strategy 
[17].therapy is considered. 
Cueing has been employed to successfully improve aspects of impaired activities in 
Parkinson’s, for aspects of Parkinson’s such as gait, has been used successfully in the past 
[18-217-10]. Cueing generally relies on the implementation of a system of temporal cues, 
where participants are provided with time-controlled auditory or haptic prompts to change 
theirinstigate or modify a behavior. 
The concept of temporal cueing as a treatment for drooling has been built on 
previous work, which has shown success in the domain of cueing,  for example in gait 
training for Parkinson’s [18]. The belief is that It is built upon observations that the training 
of a metronomic cue brings about the execution of a new motor plan, which facilitates 
walking and suppresses the impaired motor plan currently inhibiting the intended 
movement [19-21]. There is a level of automaticity in the complex movements of both 
walking and swallowing of saliva that link these two symptoms together and allow for cross 
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comparison of motor theory. Both are triggered, patterned responses involving automated 
neural processes that generally do not require conscious thinking for carrying out the 
activity. However, in the case of Parkinson’s, these automatic movements can become 
impeded when difficulties with motor initiation arise. In terms of neurophysiology, cueing is 
believed to suppress pathological basal ganglia activity through activation of corticostriatal 
pathways [19]. That is to say, the cue causes the initiation of an alternative pathway in the 
brain, also linked to motor activity, which brings about the initiation of movement that has 
been halted. 
The feasibility of cue provision to improve drooling has been minimally studied. 
Marks et al [2211], used a (now) commercially available device, in the form of a brooch, 
which emitted an auditory cue (a short ‘beep’) at regular intervals to remind the wearer to 
swallow. They found this yielded positive results for participants (n=6). Although the device 
was found to be effective for the control of drooling problems, their small sample size did 
not provide sufficient information around the effectiveness of the intervention on a wider 
population of people with Parkinson’s, nor did the authors discuss the acceptability of the 
technology they trialed with their participants. A further study by Marron et al. [2312] 
showed that wearers of the same drooling brooch reported several aspects that reduced its 
acceptability. For example, hearing impaired participants could not use the device, yet the 
auditory cue was also a source for concern for others due toin the environment, since the 
beep attracteding attention when worn, drawing into question its social acceptability. The 
product used also incorporated a switch to turn the device on and off. S, which some users 
required assistance to operate this due to their impaired fine motor skills. degeneration 
resulting from Parkinson’s. 
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In response to these drawbacks, we developed a simple- to- use wrist- worn digital 
cueing device, the PDCue (figure 1). This was iteratively designed with pwPD People with 
Parkinson’s and their caregivers in our previous work [2413].  This early study established 
usability and motor and social acceptability of the device we employed;, that it was usable 
even by individuals with marked fine motor and sensory difficulties; and that a vibratory cue 
was preferable to an auditory cue [2413].  The device delivers a silent vibratory cue, once 
per minute when switched on, to remind the person to swallow. The once per minute 
setting was decided upon in accordance with previous research which established daytime 
non-stimulated swallowing frequency in healthy adults of around one swallow per minute 
[25]. This was also The once per minute setting was decided upon in accordance with 
previous research around swallowing frequency in healthy adults (1.32 swallows per 
minute) [14] and was the preferred interval selected by Marron et al [[2312] in their study. 
There is, as yet, no literature relating to the swallowing rate of people with 
Parkinson’spwPD. 
The purpose of this the pilot study presented herein this paper was to explore the 
feasibility and acceptability of using this novel cueing device to help people with 
Parkinson’spwPD to self-manage their drooling, and to establish whether there was 
evidence of an effect on drooling severity and frequency when wearing the PDCue. We also 
wanted to explore some practicalities relating to recruitment and retention of participants 
into the study, and how appropriate our outcomes measures were, in order to inform the 
trial design of any larger scale studies which might arise.  
Figure 1 about here
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Methods 
Experimental Design
This study employed quantitative methods to examine for possible effects of the cueing 
device on perceived drooling severity and frequency. It used qualitative methods (semi-
structured exit interview) to establish opinions of participants on the acceptability and 
feasibility of the intervention program, and experiences of using the PDCue.a repeated 
measures design and looked at both between and within group differences. It first looked at 
a 2 (immediate vs delayed intervention groups) x 2 (measure times: first and second 
assessment point) design; then a 1 (all participants together once all had received 
intervention) x 3 (measure times: pre, post and 1 month after intervention) design (see fig 2 
below). The study was approved by the Newcastle and North Tyneside National Research 
Ethics Service Committee (reference: 11/NE/0257). Informed written consent was obtained 
from all participants in the study. All study data were collected by employees of 
Northumbria Healthcare NHS Foundation Trust, who were responsible for the organization 
of the project.
Participants and Recruitment 
The study was approved by the Newcastle and North Tyneside National Research Ethics 
Service Committee (reference: 11/NE/0257). Informed written consent was obtained from 
all participants in the study. All study data were collected by employees of Northumbria 
Healthcare NHS Foundation Trust, who were responsible for the organization of the project. 
Participants were primarily recruited via the regular Parkinson’s clinics at Northumbria 
Healthcare NHS Foundation Trust, but participants from Participant Identification Centers in 
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Sunderland, Gateshead and Newcastle were also included. Potential participants were 
identified by clinical staff and then contacted by a researcher via telephone with further 
information. Written information sheets were then sent to those who expressed sustained 
interest and, following a 1- week period, participants were visited in their homes to obtain 
informed consent. 
Inclusion criteria were (1) anyone with a diagnosis of Idiopathic Parkinson’s (stages I-
III in Hoehn and Yahr scale [2615]), in accordance with the UK Parkinson’s Brain Bank criteria 
[2716], (2) an acknowledged daytime drooling problem, either observed by a clinical 
professional within a Parkinson’s disease clinic or through patient self-report, and (3) an 
ability to understand and respond to the instructions given in the study. Exclusion criteria 
were (1) currently receiving pharmaceutical treatment for drooling, (2) insufficient dexterity 
with which to use the device.
A full case history was taken from each participant regarding their Parkinson’s, 
drooling, and history of swallowing difficulties. The Mini Mental State Exam [28] and 
Montreal Cognitive Assessment Test were conducted for screening purposes of cognitive 
impairment [2917]. The Unified Parkinson’s Disease Rating Scales II and III [3018] were 
conducted to gain an indication of overall disease state. All assessments were performed by 
the same researcher in the participant’s own home.
Participants were randomly allocated to either an immediate intervention group 
(n=17) or a delayed intervention group (n=11). This was to provide preliminary data for 
comparison of treatment vs no-treatment. The delayed group did not commence 
intervention until after they had completed a four-week period of no intervention. The 
randomization protocol was pre-determined using an online random number generator 
(https://www.randomizer.org/). The numbers were arranged into consecutive order 
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creating a sequence for randomizing individuals (e.g. 1- immediate, 2-immediate, 3-
delayed). If a participant left the study, their group assignment (immediate or delayed) was 
added to the end of this list to be filled by later recruits. We aimed for a 1:1 ratio, with a 
target recruitment of 30 participants (15 in each group). We fulfilled the capacity of the 
intervention group, but time restrictions meant that we were unable to complete a delayed 
start for the final two participants we had recruited. As such, we entered them into the 
intervention group leaving final numbers of 17 immediate and 11 delayed participants. This 
is a limitation of the study and is discussed further in the limitations section.
Measurements
The Parkinson’s Disease Questionnaire (PDQ-39) subtests for wellbeing, stigma and 
communication [19]; the ‘saliva’ subset of questions from the Radboud Oral Motor 
Inventory for Parkinson’s Disease (ROMP-Saliva) [3120],; and the Unified Parkinson’s 
Disease Rating Scale (UPDRS) 2.2. subtest for saliva [3018] were conducted with each 
participant at: one week before commencing use of the cueing intervention (assessment 
point 1), one week immediately after finishing the intervention (assessment point 2), and 
four weeks later at a follow up appointment (assessment point 3). For participants in the 
delayed start group, an additional baseline assessment was collected 4 weeks prior to the 
immediately pre-treatment assessment (assessment point 0). Figure 2 illustrates the time 
line.  
Figure 2 about here
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ROMP-S is a validated tool [31] for use with pwPD. It is derived from the 
unvalidated Drooling Frequency and Severity Scale (DFSS) [32] originally drawn up for 
children with cerebral palsy but employed in several other populations. It was slightly 
modified for ROMP-S, in particular by adding the option to score that one is troubled by 
(perceived) accumulation of saliva without actually drooling. The nine items, rated on 5-point 
ordinal scales that describe gradations of drooling activity, cover day and night-time 
frequency and severity of drooling, effects on speech and eating and drinking, how frequently 
one has to wipe away saliva, limitations on daily activity and social participation, and overall 
impact.     
UPDRS item 2.2. is a 5 point descriptive ordinal scale ranging from 0-4; no drooling 
(0), excess saliva but no loss (1), nighttime but not awake drooling (2), awake drooling but 
wiping not necessary (3), severe drooling with constant wiping/wet clothes (4). was collected 
4 weeks prior to assessment point 1 (assessment point 0) and was immediately followed by a 
4-week period of no intervention. 
At each assessment point, participants completed a 7-day drooling severity, 
frequency and duration diary [21]. Participants monitored their drooling over the course of 
one self-selected hour per day whenthat they would typically drool (e.g. after meal times, in 
the morning). Following Hauser et al (2004) [33] participants completed 100 mm visual 
analogue scales (VASs). They placed a cross on a 100mm line Participants placed a cross on a 
100mm line (with 0mm being ‘no problem’ and 100mm being ‘as bad as can be’) to indicate 
the number of separate incidents they felt that drooling occurred (frequency), how long in 
minutes they felt drooling occurred (duration), and how severe they felt drooling was 
(severity). This method reflects standardized methods of monitoring using paper diaries 
employed in other medical research (e.g. [34, 3522, 24]). This same diary was then used to 
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collect daily self-report from participants during the 4-week intervention period. A 
visualization of this assessment schedule can be viewed in figure 2.
Figure 2 about here
Finally, an exit interview was carried out with each individual to gather qualitative feedback 
on the participants’ experiences. A semi-structured approach was taken to probe; a) 
experiences of drooling before taking part in the study; b) experiences of drooling after 
taking part in the study; and c) perceptions around the acceptability, worthwhileness and 
effectiveness of the PDCue as a way to self-manage their drooling. 
Intervention
All participants were visited at home and received a verbal and practical tutorial on how to 
use the cueing device. They were asked to use the device for one hour a day, for a total of 
four weeks, at a time when drooling was an issue for them. Participants were asked to not 
use the device during the hour that they were self-reporting their drooling on the daily 
diary. 
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Data Processing and Analysis 
Quantitative dData were analyzed using the IBM SPSS statistical software suite (v.22, IBM 
Corp, Armonk, NY). For data collected at the ordinal, interval or ratio level, normality of 
distribution was checked by inspection of histograms and using the Shapiro-Wilk and 
Kolmogorov-Smirnov tests [3623].  None of the variables examined were considered 
normally distributed.  Data were summarized using statistics appropriate to the level of the 
data (e.g. median, inter-quartile range, frequency).  In inferential analysis, the Wilcoxon 
signed ranks test or Mann-Whitney U test was applied to ordinal, interval or ratio data and 
the Chi-squared test to categorical data.  For analysis across all 28 participants of change in 
scores from pre- to post-treatment (assessment points 1 and 2), and from pre-treatment to 
follow-up (assessment points 1 and 3) for the same variable, the Bonferroni correction was 
applied, setting significance at 2.5%.  For all other inferential tests significance was set at 
5%.  Two-tailed tests were used throughout. A repeated measures design looked at both 
between (delayed intervention versus immediate intervention) and within group 
differencesdifferences, (all participants combined to compare baseline pre-treatment, 
termination of treatment and follow-up outcomes).      
Qualitative data collected during the exit interviews were audio recorded and 
transcribed verbatim. Transcriptions were then subjected to an inductive thematic analysis 
using methods drawn from Braun and Clarke (2006) [37]. Data was summarized with short, 
one or two word codes, at the sentence-to-paragraph level. Codes were then compared to 
one-another and grouped, which led to the construction of broader themes that captured 
the core topics and concerns emerging from the data..
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Results 
Fifty-eight participants were identified for potential inclusion.  Twenty of these chose not to 
join (due to reasons such as not feeling drooling was severe enough; not having time to 
commit to research). Thirty-eight consented to participate. During the trial ten participants 
left the study. Five stated reasons of ill health, four felt the study was too much for them to 
manage at the time, and one gave no reason. The data analyzed came from the twenty-
eight remaining participants (ten female). Compliance levels for filling out diaries varied. 
Out of a possible 6,699 diary entries 5,069 (76%) were provided. The demographic and case 
history information can be viewed in Table 1. No significant biases were observed between 
the two groups with regard to any of the variables investigated.   
Table 1 about here
Intervention vs no intervention
Results for the first and second assessments with the no-intervention group, and 
assessments for the immediate intervention group before and at end of intervention, 
appear in table 2. There were no statistically significant differences between the immediate 
and delayed intervention groups at the initial baseline assessment. There were no 
significant changes in ROMP-S, UPDRS 2.2 or Diary reports (VAS measurements) for the no-
intervention group during the 4 weeks of no treatment. There were also no statistically 
significant changes to ROMP-S and UPDRS 2.2 in the intervention group when comparing 
pre- versus termination of treatment. Patient perceived changes on the VASs did show 
significant improvement in the intervention group for overall severity, but for frequency of 
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drooling improvement was borderline (p=0.06) and perceived amount of time (duration) of 
drooling did not alter significantly.   
Table 2 presents data for the delayed start (at assessment points 0 and 1) and immediate 
start (at assessment points 1 and 2); representing a period of no intervention for the 
delayed start group and intervention for the immediate start group.  The difference 
between the two groups in change from baseline score are compared across the outcomes 
investigated.  Only the change in drooling severity from the diaries was significantly 
different between the two groups; this increased (i.e. got better) for the intervention group 
but stayed the same for the no intervention group.
Table 2 about here 
Comparison of pre- and post-treatment scores across all participants 
Given that there appeared to be no placebo effect in the delayed intervention group during 
the no intervention phase (i.e. no significant improvement in any scores), once both groups 
had completed intervention their scores were combined to provide a larger group (n=28) for 
comparison of pre- versus post treatment versus follow-up assessment    
Between treatment termination and four week follow-up assessment four 
participants left the study (two moved on to Botox treatment immediately after the 
intervention ended, one experienced significant health decline and one moved abroad). This 
left 24 participants available for longer-term follow-up assessment comparisons. Outcomes 
are summarized in table 3.  
We compared measures before vs after intervention vs at follow-up for all 28 participants 
(assessment points 1, 2 and 3 respectively). Twenty-four participants were available for 
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follow up assessment one month following completion of the intervention. Of the other 
four, two moved on to Botox treatment immediately after the intervention ended, one 
experienced significant health decline and one moved abroad. Outcomes are summarized in 
table 3.  There were significant improvements as measured by the Unified Parkinson’s 
Disease Rating Scale item for drooling and saliva from pre-treatment to follow-up, and from 
the self-reported diary for drooling severity (from pre-treatment to follow-up), frequency 
(pre-treatment to post treatment, and pre-treatment to follow-up) and duration (pre-
treatment to post treatment, and pre-treatment to follow-up). 
Table 3 about here 
ROMP-S ratings saw no significant change comparing scores at pre- versus at 
termination of treatment. UPDRS 2.2. ratings showed a trend towards significance but were 
still statistically non-significant. VAS patient perceptions of change in overall severity, 
duration and frequency of drooling all evidenced significant improvements. 
To examine whether scores returned to baseline status once intervention finished, 
baseline scores were compared with four weeks post treatment assessments. ROMP-S 
demonstrated a move towards significance (but was still not statistically significant), whilst 
UPDRS 2.2. now showed a significantly better status. The VAS ratings all showed strongly 
significant improvements, including after adjustments for multiple testing.  The findings 
suggest maintenance or even improvement of status during the follow-up phase. 
Exit interviews
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Twenty-seven participants were available for exit interview. One participant had a 
significant health decline and was thus unavailable. Interviews lasted ameann average of 
17:03 minutes (shortest 6:29-longest 36:37). Following procedures outlined in the 
methodology section, There were a total of 26 thematic codes applied to the data. A total of 
312 extracts of transcript were assigned these codes (ranging from 1 to 22 extracts per 
code). A total of 45 higher level themes were then constructed from this qualitative data 
analysis, which will beare summarised below. 
The first theme to arise was the impact of drooling on the lives of the participants. 
By far, the most discussed impact of drooling issues pre-treatment was embarrassment 
(13/27), with several participants discussing emotional distress “It really dominated my 
life…it was most distressing, psychologically distressing…it clearly ruled my thinking…in that I 
was always clasping this grubby handkerchief just in case” (P14), and social withdraw, “At 
least once a day it would happen. I was out with company and it made me feel very 
embarrassed. I tend to withdraw, avoid going out really. Eat on my own. I am pretty strict 
about manners, and I thought it looked horrible” (P12). Several participants (4/27) also 
discussed physical discomfort that they experienced—constant wetness, changing of 
handkerchiefs, painful sores around the mouth. 
The second theme related to challenges around previous experiences of drooling 
treatment. Several participants (3/27) had previous experience of Botox, however, for a lot 
of participants (8/27), Botox was not an option they would have considered. These 
participants discuss a lack of willingness to take additional medication; “when I saw the 
consultant they said I could go and have Botox, an injection. I didn’t want to take any more 
drugs” (P22). Botox was associated with words such as “toxic” (P25) and “poison” (P26) and 
there was a clear preference for avoiding it, and other additional medication, if possible; “I 
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think if you can have something that avoids taking drugs I think that’s great” (P4). These 
participants, unsurprisingly, preferred the PDCue as a behavioural treatment option; “I’d 
rather have the watch” (CP7). 
Theme three related the effect of the PDCue on drooling. Of the 27 interviewed 
participants, there was a reported positive effect for 22, indicating that the majority of 
participants successfully engaged with the intervention and found it to be a worthwhile 
option for supporting the self-management of drooling. Theme four then related 
toParticipants also discussed emotional benefits which arose as a result of the PDCue 
intervention, including improvements to self-esteem, confidence and feelings of control. 
The final theme related to reports of generalizsation and habituation. There were 
several cases of participants reporting a generalization effect, wherein they felt an increase 
in swallowing frequency was being carried over to times when they were not wearing the 
PDCue (9/27). P4 said “Even when I wasn’t wearing the [PDCue] every now and again I think, 
“Oh yes, you haven’t swallowed. I need to swallow””. P3 also noted “even when I wasn’t 
wearing it I was much more conscious of it”. Although unexpected, P26 also discussed an 
improvement to his night time drooling “I’ve hardly been drooling at all. No, I haven’t. Even 
during the night I haven’t been”. 
There were a small number of participants (3/27) however who reported becoming 
habituated to the cues, e.g. P10 “there were occasions when I had the watch on, I seemed to 
have got so used to it that I didn’t get any indication”. However, these participants reported 
a positive effect from the intervention, despite this habituation. 
Discussion
This pilot study aimed to explore the feasibility, usability and acceptability of wearing a 
wrist-worn vibratory cueing device to improve drooling in people with Parkinson’s, and to 
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establish whether there was evidence of an effect of the device on drooling severity, 
frequency and impact. A total of 28Twenty-eight people completed a month-long 
intervention with the device, using it for an hour a day. These participants Altogether they 
showed significant improvement on severity (p=0.031), frequency (p=<0.001), and duration 
(p=0.001) of drooling when comparing results from the self-reported diary VASs collected 
pre and post intervention. These improvements were also seen to remain at follow up 
assessment 4 weeks post-treatment compared to their pre-intervention baseline. A significant 
improvement was also seen in the UPDRS 2.2 saliva subtest (p=0.010) when comparing the 
pre-intervention and follow up assessment time points. Based on this we conclude there is 
some evidence to indicate that the device can be successful in improving saliva control, not 
only when wearing the PDCue but also when not using it or after intervention has been 
withdrawn. 
Comments from the interviews confirm that people are disturbed by their drooling 
and that lesser drooling brings benefits for psychosocial well-being. Participants were 
satisfied with manipulating the device and found it acceptable to wear. They perceived the 
gains seen made wearing the device worthwhile. This is further reflected in comments 
participants made in the exit interviews concerning the perceived positive effects of the 
intervention device. Responses showed that 22/27 participants explicitly reported that they 
had noticed benefits to their drooling, with several stating that it was a preferable 
treatment option to other pharmaceutical interventions. In a larger trial it is unlikely that 
this interview-based approach could be undertaken at scale. The development of a 
questionnaire, drawing on the themes outlined from the qualitative data could be an 
approach to capturing data of this kind. 
The lack of positive change in the delayed treatment group during their no-
intervention phase suggests that change was not accounted for by a placebo effect from 
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being recruited to the study, being assessed, completing the diary exercise, nor from 
receiving information about drooling and drooling interventions in general. There was no 
improvement despite written (in the study information pack) and oral discussion that more 
frequent swallowing may benefit saliva loss. Whilst the present data suggest placebo effect 
does not play a significant role here, in a definitive trial a more active comparator condition 
should be introduced.  
Our results showed a measurable change in score in the UPDRS item for drooling, 
between baseline and 4 week follow-up, lending additional weight to the improved VAS 
responses that participants provided. However, we did not observe any significant 
differences in the ROMP-S overall score. This may indicate that the types or level of changes 
experienced over the intervention period were not sufficient for this tool to capture. It 
could be that employing an overall score across multiple dimensions rather than analyzing 
each item separately masked significant gains in some areas. For instance, there may have 
been no change in night time drooling score, or even, after a short period, no shift in overall 
impact. Nevertheless, frequency of having to wipe the mouth or perceived excessive saliva 
in the mouth may have altered, but these improvements failed to make a significant 
difference in overall score against the non-altered variables.  A similar factor may be at work 
in the lesser (compared to VASs) sensitivity to change of the UPDRS saliva item, since this 
scale combines several features which might actually vary independently (e.g. day vs night 
drooling; perceived excess saliva in mouth; frequency vs severity) in one scale which might 
actually vary independently. Significant improvement in one sub-dimension may be missed 
if the other dimensions do not alter. This would mask changes in one of the sub-dimensions. 
Further analyses of individual items prior to a definitive trial may aid in separating out which 
aspects of drooling are more or less susceptible to influence through cueing. 
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When comparing diary scores at baseline between groups (immediate vs delayed) we 
observed no significant differences, except on self-reported severity (p=0.010), which 
reduced (i.e. got better) in the intervention group but stayed the same in the no 
intervention group. This result in itself deserves attention; in the delayed group, the other 
perceived measures collected from the diary (duration and frequency) increased (i.e. got 
worse), which may indicate that the process of completing the diary increased awareness of 
drooling. However, we had considered that this, paired with knowledge that increased 
swallowing frequency could reduce drooling (provided in the information sheet and during 
the informed consent procedure) might actually lead to an improvement in drooling in the 
delayed group. However, this was not the case, again furthering evidence that our results 
were not due to placebo effect. 
Another factor to consider for a larger trial is data completeness for the diaries. We 
had a 76% completion rate across the study. Although this is not dissimilar to other studies 
[e.g. 33], a larger trial A larger RCT would need to consider the time requirements of 
participants and the burden of the study to self-report, although this is not dissimilar to 
other studies [21]. . We make the suggestion that completing the diary throughout the 
entirety of the study is not required. O, only completing the diary for one week pre and 
post-intervention (and again at follow up) would be enough in a follow up trial, as these 
were the results that we eventually focused on in our analysis. 
Self-reported diaries are heavily used in clinical research as a way to monitor the progress of 
treatment and log patients’ activities over time, without the requirement for a researcher to 
be present, despite longstanding reported issues with compliance (e.g. [34, 35]). Recent 
research into tools to support self-report in Parkinson’s research has provided clear 
recommendations for improving practice, with Vega et al. finding 99% compliance with their 
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paper-based tool measuring self-reported symptoms over several months with a small 
number of participants [38]. However, another solutions would be to introduceConsidering 
usage logs, collected automatically by the device, which would also provide an indication of 
participant compliance without the need for the diary. 
Self-reported diaries are heavily used in clinical research as a way to monitor the progress of 
treatment and log patients’ activities over time, without the requirement for a researcher to be 
present, despite longstanding reported issues with compliance (e.g. [24]). Recent research 
into tools to support self-report in Parkinson’s research has provided clear recommendations 
for improving practice, with Vega et al. finding 99% compliance with their paper-based tool 
measuring self-reported symptoms over several months with a small number of participants 
[25]. 
Our results showed a measurabl  change in score in the Unified Parkinson’s Disease 
Rating Scale subtest for drooling, which adds additional weight to the diary responses that 
participants provided. However, we did not observe any significant changes in the 
Parkinson’s Disease Questionnaire-39 (PDQ-39) subtests for wellbeing, stigma and 
communication; nor did we observe any significant differences in the Radboud Oral Motor 
Inventory for Parkinson’s disease saliva subtest. PDQ-39 is not designed to detect changes in 
drooling impact. The lack of significant changes may also indicate that the types or level of 
changes experienced over the intervention period were not sufficient for these tools to 
capture. Further work, prior to a larger RCT, is required to ensure that the impact of the 
PDCue intervention in a larger cohort of participants could be appropriately measured. The 
qualitative work that we completed as part of this pilot trial showed that, during exit 
interviews, 22 participants explicitly reported that they had noticed benefits to their 
drooling, with several stating that it was a preferable treatment option to other 
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pharmaceutical interventions. All participants felt the intervention and device were 
acceptable and usable.  However, in a larger trial it is unlikely that this qualitative approach 
could be undertaken at scale. The development of a questionnaire, drawing on the themes 
outlined from the qualitative data could be an approach to capturing data of this kind. In 
addition, the interviews highlighted that a small number of participants noted habituation 
to the device. Whilst we did not set up the study to answer the question about habituation 
definitively, future research should look at whether this is a factor in whether the device is 
effective or not for an individual. In the present study, in as far it was highly effective for 
some, then we can assume that habituation is not an all-pervasive problem. However, in 
future we suggest longer follow-up times to look at possible wearing off effects.
The concept of temporal cueing as a treatment for drooling has been built on 
previous work which has shown success in the domain of cueing for gait training for 
Parkinson’s [7]; built upon observations that the training of a metronomic cue brings about 
the execution of a new motor plan, which facilitates walking and suppresses the impaired 
motor plan currently inhibiting the intended movement [8-10]. There is a level of 
automaticity in the complex movements of both walking and swallowing of saliva that link 
these two symptoms together and allow for cross comparison of motor theory. Both are 
triggered, patterned responses involving automated neural processes that generally do not 
require conscious thinking for carrying out the activity. However, in the case of Parkinson’s, 
these automatic movements can become impeded when difficulties with motor initiation 
arise. In terms of neurophysiology, cueing is believed to suppress pathological basal ganglia 
activity through activation of corticostriatal pathways [8]. That is to say, the cue causes the 
initiation of an alternative pathway in the brain, also linked to motor activity, which brings 
about the initiation of movement that has been halted. 
Page 22 of 39
https://mc.manuscriptcentral.com/jrate
RATE Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
The body of literature exploring cueing for drooling as a symptom is minimal, with 
only small-scale preliminary work by Marks et al [2211] and Marron et al [2312] being the 
only examples exploring this space. As such, our work builds upon this nascent body of 
literature to provide additional evidence that cueing for drooling might be an effective way 
to manage the symptom, with the qualitative aspects of our study additionally 
demonstrating reports around increased feelings of control, confidence and self-esteem 
post intervention. In addition, we build on our previous work [2413] to report that 
acceptance and usability of our tool has been confirmed with a larger and more varied 
group of participants over a longer period of time. Our cueing approach warrants further 
exploration in a larger scale trial.
Study Limitations 
There are several provisos in interpreting the current data. Firstly, one assumes that 
participants were wearing the devices as requested, for a designated hour each day. 
However, we did not collect precise usage logs. In future work there would be benefit in 
utilizing a more objective approach, e.g. through digital usage logs collected directly through 
the device (i.e. using an accelerometer to provide data on when the device is switched on 
and being used). Secondly, we asked participants to self-select an hour within which to self-
monitor their drooling, at times when drooling was a problem. Whilst participants may have 
selected a self-perceived period of more susceptibility to drooling, it remains unclear how 
severe their chosen hour might have been. Further laboratory-based work, employing 
objective measures of physiological drooling (e.g. objective swallow frequency 
measurement, or saturated gauze weight measurement) would add insight into whether or 
not orally retained saliva objectively decreased through use of the device. This would also 
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remove, at least in laboratory conditions, the use of self-report diaries that may be open to 
recall bias. For field- testing, employing devices capable of measuring swallowing events in 
naturalistic situations (e.g. using an in-ear microphone) would be beneficial. 
Finally, although 30 participants was the sample size intended for this first stage 
feasibility trial, we did not have matched numbers between the delayed and immediate 
groups. The intentions was to have 15 participants in each, but time constraints meant that 
we were unable to fully recruit to our delayed group (with 4 participants remaining). We 
made a decision to include a final 2 participants in the study as immediate intervention 
participants. Future studies implementing two treatment strands should not have this 
problem in future work, however future researchers should also consider randomisation 
approaches that allow for equal participant numbers throughout the recruitment process 
(e.g. even vs odd participant numbers to each strand). In addition, whilst the results of our 
pilot work delivered some positive outcomes, sufficient to suggest the cueing device may be 
effective, a more definitive answer awaits a trial involving larger numbers in a more highly 
powered study and with an active intervention comparator. 
Conclusions
This study has indicated that our cueing device was acceptable and usable, and that the 
intervention could be a feasible first step for clinicians, before moving on to pharmaceutical 
options, which have been shown to have potential complications. Whilst the next step of 
this research will require a larger multi-center trial to elucidate whether these results are 
replicable and clearer in a larger population, and to look at the characteristics of responders 
vs non-responders to the treatment, the information presented within this paper has 
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provided important, preliminary data around the effect that the cueing intervention could 
have and issues to address in the development of outcome measures. 
Clinical messages
 Providing a regular vibratory cue, through the PDCue device was shown to be an 
effective treatment for reducing perceived drooling in the great majority of participants.
 Participants accepted PDCue and remained motivated to self-manage their drooling with 
the device.
 Further studies are needed to confirm the beneficial effects that we observed and for 
the refinement of outcome measures.
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Figure 1: the cueing device 
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Delayed  
Intervention 
(n=11)
Immediate 
Intervention  (n=17)
Significance
Demographics   
Median age in years (IQR) 75 (65 to 79) 72 (65.5 to 78.5) U = 89.0, z = 0.212, 
p = 0.832
Median years since PD 
diagnosis (IQR)
5 (3 to 8) 7 (2.5 to 10) U = 78.0, z = 0.732, 
p = 0.464
N of females (%) 3 (27%) 7 (41%) X2(1) = 0.562, 
p = 0.689 
N of participants living 
alone (%)
1 (9%) 5 (29%) X2(1) = 1.638, 
p = 0.355  
Overall  Parkinson’s 
severity (SD)
- Median UPDRS II 
and III score 
combined (IQR)
- Hoehn & Yahr stage
44 (39 to 70)
II: 6 (55%)
III: 3 (27%)
IV: 2 (18%)
53 (35 to 81) 
II: 7 (41%)
III: 8 (47%)
IV: 2 (12%)
   
 
U = 76.5, z = 0.800, 
p = 0.424     
X2(2) = 1.115, 
p = 0.573
Initial perception of 
drooling severity, self-
reported by the participant 
N (%)
Mild=  4 (36%)
Moderate= 5 
(46%)
Severe= 2 (18%)
Mild= 9 (53%)
Moderate= 5 (29%)
Severe= 3 (18%)
X2(2) = 0.878, 
p = 0.778  
Median months since 
drooling first noticed (IQR)
24 (12 to 36) 12 (9.5 to 24) U = 75.0, z = 0.888, 
p = 0.375
N of participants with 
previous drooling 
treatment (%)
3 (27%) 5 (29%) X2(1) = 0.015,
 p = 1.000
N of participants with 
reported swallowing 
problems (%)
7 (64%) 7 (41%) X2(1) = 1.348,
 p = 0.246
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Assessment Delayed group (n=11) Intervention group (n=17) Significance 
of between 
group 
difference 
between the 
two groups 
of change 
from 
baseline
Assessment 
point 1 
(T0)0
Median 
(IQR)
Assessment 
point 2 
(T1)1
Median 
(IQR)
Assessment 
point 1 (T0)
Median 
(IQR)
Assessment 
point 2 (T1)
Median 
(IQR)
Mann-
Whitney U 
test
PDQ-39   
Wellbeing 5 (4 to 13) 5 (4 to 8) 7 (3.5 to 12) 8 (3 to 10.5) U = 77.0, 
z=0.784, 
p=0.433
Stigma 7 (1 to 9) 4 (1 to 6) 3 (1 to 7) 3 (0 to 6.5) U = 66.0, 
z=1.311, 
p=0.190
Communication 4 (2 to 5) 4 (2 to 9) 4 (2.5 to 
6.5)
6 (2 to 7) U = 92.5, 
z=0.050, 
p=0.960
ROMP- Saliva 20 (17 to 
25)
19 (17 to 
30)
22 (16 to 
23)
22 (17 to 
25.5)
U = 83.0, 
z=0.497, 
p=0.619
UPDRS 2.2 
(Saliva and 
drooling 
subtest)
3 (1 to 3) 3 (1 to 3) 3 (3 to 4) 3 (2 to 4) U = 69.0, 
z=1.212, 
p=0.225
Drooling Diary   
Severity 1 (0 to 4) 1 (1 to 5) 3 (1.5 to 5) 1 (0 to 2.5) U = 39.5, 
z=2.575, 
p=0.010
Duration (No. 
minutes 
drooling 
occurred in one 
hour)
1 (0 to 5) 2 (0.5 to 10) 5 (1 to 11) 1 (0 to 4.5) U = 63.0, 
z=1.440, 
p=0.150
Frequency (No. 
instances in one 
hour)
1 (0 to 4) 3(1 to 4) 3 (1 to 4.5) 1 (0 to 3) U = 54.0, 
z=1.876, 
p=0.061
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Assessment Entire 
group 
(n=28)
Significance of difference 
 Assessment 
point 1 (T0)
Median 
(IQR)
Assessment 
point 2 (T1)
Median 
(IQR)
Assessment 
point 3 (T3)
Median 
(IQR)
Assessment 
points 1 
(T0) to 2 
(T1)
Assessment 
points 1 
(T0) to 3 
(T2)
PDQ-39   
Wellbeing 4 (6 to 10) 6 (3.25 to 
10)
7 (4.25 to 
9.75)
Z = 1.032, p 
= 0.302
Z = 0.316, p 
= 0.752
Stigma 3 (1 to 6.75) 3.5 (0 to 7) 2 (0 to 6) Z = 0.835, p 
= 0.404
Z = 0.949, p 
= 0.343
Communication  4 (2.25 to 7) 4.5 (2 to 6) 3 (1.25 to 
5.75)
Z = 0.523, p 
= 0.601
Z = 1.150, p 
= 0.250
ROMP- Saliva  20.5 (16 to 
23.75)
20 (16.25 to 
24.75)
17 (15 to 
23.5)
Z = 0.275, 
p = 0.783
Z = 1.800, 
p = 0.072
UPDRS 2.2 
(Saliva and 
drooling 
subtest) 
3 (3 to 4) 3 (2 to 4) 2 (1 to 3) Z = 1.801, 
p = 0.072
Z = 2.569, 
p = 0.010
Drooling Diary   
Severity  3.14 (2.42) 1.18 (1.57) 1.14 (1.51) Z = 2.151, 
p = 0.031
Z = 2.809, 
p = 0.005
Duration (No. 
minutes 
drooling 
occurred in one 
hour)
7.45 (10.64) 4.75 (11.55) 1.86 (2.73) Z = 3.362, 
p = 0.001
Z = 2.631, 
p = 0.009
Frequency (No. 
instances in one 
hour)
4.18 (5.68) 1.80 (2.32) 1.16 (1.47) Z = 3.982, 
p < 0.001
Z = 3.606, 
p < 0.001
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